Groups launch registry to promote SPECT for prostate cancer

By staff writers

April 21, 2021 -- The Oncidium Foundation and Telix Pharmaceuticals have launched a registry to promote the use of SPECT with a prostate-specific membrane antigen (PSMA) agent for prostate cancer detection.

The Nobody Left Behind (NOBLE) Registry is an international clinical collaboration that aims to promote PSMA SPECT imaging for prostate cancer with a technetium-99m-labeled radiotracer. The registry announced the dosing of the first patient at University College Hospital in Ibadan, Nigeria.

The NOBLE Registry committee is comprised of investigators at eight sites worldwide and aims to deliver and publish real-world evidence and clinical practice guidelines related to SPECT imaging and prostate cancer.

Copyright © 2021

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking